The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy (Q41687656)

7 October 2017

1 reference

title

The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy (English)

1 reference

7 October 2017

Szekeres T

1

1 reference

7 October 2017

Fritzer-Szekeres M

series ordinal

2

1 reference

7 October 2017

Elford HL

series ordinal

3

1 reference

7 October 2017

publication date

1 January 1997

1 reference

Critical Reviews in Clinical Laboratory Sciences

7 October 2017

published in

1 reference

7 October 2017

volume

34

1 reference

7 October 2017

issue

6

1 reference

7 October 2017

page(s)

503-528

1 reference

Reduction of Ribonucleotides

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Role of ribonucleotide reductase in expression in the neoplastic program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Enzymology of cancer cells (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Combination chemotherapy directed at the components of nucleoside diphosphate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Structure-activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Efficacy of a hydroxyl radical scavenger (VF 233) in preventing reperfusion injury in the isolated rabbit heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Inhibitors of ribonucleotide reductase alter DNA repair in human fibroblasts through specific depletion of purine deoxynucleotide triphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Hydroxyurea therapy in chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Transgenic mouse model of pharmacologic induction of fetal hemoglobin: studies using a new ribonucleotide reductase inhibitor, Didox

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Biochemical modulation of arabinosylcytosine for therapy of leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Targeting Iron-Dependent DNA Synthesis with Gallium and Transferrin-Gallium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Reduction of the tyrosyl radical and the iron center in protein R2 of ribonucleotide reductase from mouse, herpes simplex virus and E. coli by p‐alkoxyphenols

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Antileukemic activity studies and cellular pharmacology of the analogues of 2-hydroxy-1H-isoindole-1,3-dione (HISD) alone and in combination with cytosine arabinoside (ara-C) against human leukemia cells CEM/0.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2′-β-fluoro-2′,3′-dideoxyadenosine in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10408369709006424

10.3109/10408369709006424

21 January 2018

Identifiers

DOI

1 reference

7 October 2017

1 reference